Slingshot members are tracking this event:

Alere to Initiate Voluntary Withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring System

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details  Alere is working with the FDA to determine the most appropriate timing for product discontinuation and will provide guidance on transitioning patients to an alternate solution to allow them to continue anti-coagulation monitoring in the least disruptive manner possible.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Inratio, Pt/inr Monitoring System, Anti-coagulation